AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mutated Ovarian Cancer

 AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mutated Ovarian Cancer

AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mutated Ovarian Cancer

Shots:

  • The P-III SOLO-1 study involves assessing of Lynparza (300mg, bid) as a maintenance monothx. vs PBO in 391 patients in a ratio (2:1) with newly diagnosed BRCAm advanced ovarian cancer following 1L Pt.-based CT for ~2yrs. or until disease progression
  • Five-year follow-up data demonstrated a 67% reduction in risk of disease progression or death, improvement in PFS (56 vs 13.8mos.), patients remained free from disease progression (48.3% vs 20.5%), the median duration of treatment (24.6 vs 13.9mos.), presented at ESMO 2020
  • The P-III SOLO-1 met its 1EPs of PFS in Jun’2018, which formed the basis of approvals in the US, the EU, Japan, China, and other countries. Lynparza is a first-in-class PARP inhibitor acts by targeting DDR in cells/tumors harboring a deficiency in HRR (BRCA1& 2 mutation)

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: The Conversion

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post